Workflow
利鲁平
icon
Search documents
速递|给药12周减重6.83%,华东医药公布GLP-1口服片减重Ⅱ期重要结果
GLP1减重宝典· 2025-08-09 03:03
整理 | GLP1减重宝典内容团队 近日,华东医药股份有限公司(以下简称"公司")自主研发的1类创新药口服小分子GLP-1受体激动剂HDM1002的减重Ⅱ期研究结果发 布。研究结果显示,HDM1002片在减轻体重和改善代谢方面展现出良好效果,且安全性和耐受性良好,为开展后续进一步临床研究提 供了充分且有力的依据。 安全性结果显示:大多数TEAE和TRAE的严重程度为轻度,无重度AE。HDM1002组最常见的TEAE为胃肠道事件,发生率前三位的依 次为恶心、呕吐和腹泻,严重程度均为轻度至中度。HDM1002各剂量组均未观察到肝酶异常升高的趋势。 此次HDM1002 在减重Ⅱ期临床试验中取得优异结果,是该药物研发的重要里程碑之一。根据此次Ⅱ期研究结果,经药品审评中心 (CDE)批准, HDM1002减重Ⅲ期临床研究正在进行中。目前,围绕GLP-1靶点,公司已构筑了包括口服片剂、注射剂在内的长效及 多靶点全球创新药和生物类似药相结合的全方位和差异化的产品管线。其中,公司利鲁平为国内首个获批降糖与减重双适应症的利拉鲁 肽注射液,司美格鲁肽注射液降糖适应症已申报上市,减重适应症正在开展Ⅲ期临床;创新药方面,除HDM10 ...
华东医药2025年一季报稳定发力,扣非归母净利润达历史最好水平,创新成果加速兑现
Quan Jing Wang· 2025-04-24 13:09
Core Insights - The company reported a stable growth trend in Q1 2025, with revenue of 10.736 billion yuan, a year-on-year increase of 3.12%, and a net profit of 915 million yuan, up 6.06% [1] - The pharmaceutical industrial sector continues to be a key growth driver, with core subsidiary China East Pharmaceutical achieving revenue of 3.621 billion yuan, a 6.52% increase, and a net profit of 843 million yuan, up 12.20% [2] - The company is focusing on innovation, with over 80 projects in its pipeline, and has significantly increased R&D investment by 49.60% to 880 million yuan in Q1 2025 [4] Business Segments - The innovative drug sales in the pharmaceutical industrial sector are gaining momentum, particularly with the expansion of reimbursement indications for the Bai Ling series products [2] - The CAR-T product, Zewokaiolun, has shown strong sales performance, with over 200 certified medical institutions and 154 effective orders placed by the partner company [3] - The company’s self-developed GLP-1 receptor agonist, HDM1002, has entered the final stages of clinical trials, indicating a robust pipeline in the endocrine field [5][6] Medical Aesthetics - The medical aesthetics segment is showing resilience, with the subsidiary Sinclair achieving approximately 238 million yuan in revenue, a 24.37% increase from the previous quarter [9] - The company has a portfolio of 40 high-end medical aesthetic products, with 26 already launched globally, indicating a strong market presence [9] - New products in the medical aesthetics field, including injectable products, are expected to drive further growth in 2025 [10] Future Outlook - The company aims to leverage its innovative capabilities and product differentiation to expand its market share in the medical aesthetics sector, which is projected to grow steadily [12] - The pharmaceutical industrial sector is expected to maintain a strong growth trajectory, supported by ongoing market expansion and product pipeline development [12] - The overall performance in Q1 2025 reflects the company's commitment to innovation and growth, positioning it for future success in the pharmaceutical and medical aesthetics industries [12]